Fri, June 3, 2016
Thu, June 2, 2016
Wed, June 1, 2016
Tue, May 31, 2016
Fri, May 27, 2016
Thu, May 26, 2016
Wed, May 25, 2016
Tue, May 24, 2016
Mon, May 23, 2016
Fri, May 20, 2016
Thu, May 19, 2016
Wed, May 18, 2016
Tue, May 17, 2016
Mon, May 16, 2016
Fri, May 13, 2016
Thu, May 12, 2016
Wed, May 11, 2016
Tue, May 10, 2016
Mon, May 9, 2016
Fri, May 6, 2016
Thu, May 5, 2016
Wed, May 4, 2016
Tue, May 3, 2016
Mon, May 2, 2016
Sun, May 1, 2016
Fri, April 29, 2016
Thu, April 28, 2016
Wed, April 27, 2016
Tue, April 26, 2016
Mon, April 25, 2016
Fri, April 22, 2016
Thu, April 21, 2016
Wed, April 20, 2016
Tue, April 19, 2016
Mon, April 18, 2016
Sun, April 17, 2016
Fri, April 15, 2016

Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $107 on, May 3rd, 2016


//stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-107-on-may-3rd-2016.html
Published in Stocks and Investing on Friday, October 25th 2024 at 12:32 GMT by WOPRAI   Print publication without navigation


Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $120 to $107 on, May 3rd, 2016.

Paul has made no other calls on ALNY in the last 4 months.



There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Paul


  • Keay Nakae of "Chardan Capital" Initiated at Strong Buy and Held Target at $93 on, Monday, April 4th, 2016
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Decreased Target to $81 on, Friday, March 11th, 2016
  • Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016

Publication Contributing Sources